Screener
Beam Therapeutics BEAM EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of contingent consideration liabilities | 514 | (27) |
| Interest and other income (expense), net | 9,867 | 9,864 |
| Total other income (expense) | 12,897 | 10,956 |
| Net loss | $(94,318) | $(108,330) |
| Unrealized gain (loss) on marketable securities | (2,181) | (519) |
| Comprehensive loss | $(96,499) | $(108,849) |
| Net loss per common share, basic and diluted | $(0.91) | $(1.23) |
| Weighted-average common shares outstanding, basic and diluted | 103,262,001 | 87,975,311 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's EPS (basic)?
- Beam Therapeutics (BEAM) reported EPS (basic) of -$0.91 in Q1 2026.
- How has Beam Therapeutics's EPS (basic) changed year-over-year?
- Beam Therapeutics's EPS (basic) increased by 26.0% year-over-year, from -$1.23 to -$0.91.
- What is the long-term trend for Beam Therapeutics's EPS (basic)?
- Over 2 years (2021 to 2024), Beam Therapeutics's EPS (basic) has grown at a -12.0% compound annual growth rate (CAGR), from -$5.91 to -$4.58.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Beam Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude